Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an injection restore hearing? new trial tests DX243 in older adults

NCT ID NCT07637981

Disease control Sponsor: Dendrogenix Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests an investigational drug called DX243 in people with mild to moderate age-related hearing loss. Participants receive daily injections of DX243 or a placebo for 29 days. The study checks whether the drug is safe and whether it improves hearing, using speech-in-noise tests and questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DX243
What this could lead to
If effective, DX243 could offer a new treatment to improve hearing in older adults with mild to moderate hearing loss.
What could go wrong
This is an early-phase trial with only 24 participants, so results may not apply broadly. Safety and efficacy are still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient having self-reported recent difficulty hearing in noisy environments for at least 6 months prior to screening. * Patient exhibiting a speech-in-noise hearing deficit in at least one ear; * Patient having audiometrically-defined normal hearing or up to moderately severe hearing impairment Exclusion Criteria: * Current tympanic membrane perforation; * Current acute or chronic otitis; * Genetic hearing loss; * Symmetric or asymmetric severe hearing loss; * Any therapy known as ototoxic; * Acute chronic otitis media or otitis externa terminated less than 7 days prior to randomisation; * History of chronic inflammatory or suppurative ear disease or cholesteatoma; * History of otosclerosis, suspected perilymph fistula or membrane rupture, suspected retro-cochlear lesion, barotrauma; * Prior ear surgery of any kind; * Fluctuating hearing loss; * Patient with conductive hearing loss; * History of Meniere's disease, autoimmune hearing loss, radiation-induced hearing loss, acoustic neuroma

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age related hearing loss are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

presbycusis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age related hearing loss

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre hospitalier Universitaire de Liège Sart Tilman

    RECRUITING

    Liège, Liège, 4000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.